NEW YORK (GenomeWeb News) – Sequenom has licensed exclusive worldwide rights, except for Hong Kong, to intellectual property covering digital PCR and other non-invasive prenatal diagnostic technology from the Chinese University of Hong Kong.
The license expands San Diego-based Sequenom’s IP portfolio covering prenatal diagnostic methods using fetal nucleic acids obtained from maternal samples.
The firm said that the digital PCR is technology-independent and was developed and validated on its MassArray platform and Fluidigm’s platform. Sequenom said it can be adapted for any of the existing digital PCR platforms. In addition, it noted that the IP includes methods of analysis for noninvasive Down (trisomy 21), Edward (trisomy 18), Patau (trisomy 13), and other chromosomal aneuploidy syndrome diagnoses or other autosomal recessive disorders using digital PCR.
“Over the past several years, we have acquired numerous intellectual property assets to protect our plans to enter the noninvasive prenatal genetic diagnostic market and this license is another important addition to our broad and deep IP position in this area,” Harry Stylli, president and CEO of Sequenom, said in a statement today.
In early June, Sequenom announced that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes. The firm intends to continue development of the test throughout 2008 and then transfer the technology to lab partners.